SPRB catalyst calendar

SPRUCE BIOSCIENCES, INC.

Upcoming catalysts
2
Cash runway
33.1 months
Cash & investments
$96M
Phase 3 programs
1

SPRUCE BIOSCIENCES, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on October 16, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 33.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 6 concluded trials, 33% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 16, 2026 est. Next quarterly earnings (projected) Earnings —
August 15, 2033 Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) Trial Milestone Phase 3

Track SPRB alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open SPRB in the tracker

Recent history

DateEventTypePhase
August 12, 2026 Quarterly results filed (8-K) Earnings —
July 27, 2026 8-K filed: Leadership change Corporate —
May 13, 2026 Quarterly results filed (8-K) Earnings —
April 22, 2026 8-K filed: Material agreement, Other event Corporate —
March 9, 2026 Quarterly results filed (8-K) Earnings —
February 5, 2026 8-K filed: Reg FD disclosure, Other event Filing —
January 8, 2026 Quarterly results filed (8-K) Earnings —
December 15, 2025 8-K filed: Leadership change Corporate —
December 12, 2025 8-K filed: Leadership change Corporate —
November 10, 2025 Quarterly results filed (8-K) Earnings —
October 17, 2025 8-K filed: Leadership change Corporate —
October 8, 2025 8-K filed: Material agreement, Other event Corporate —
August 14, 2025 Quarterly results filed (8-K) Earnings —
July 24, 2025 8-K filed: Reg FD disclosure Filing —
June 12, 2025 8-K filed: Listing / standard notice, Other event Corporate —
May 29, 2025 8-K filed: Material agreement, Other event Corporate —
May 6, 2025 Quarterly results filed (8-K) Earnings —
April 25, 2025 8-K filed: Listing / standard notice Corporate —
April 15, 2025 Quarterly results filed (8-K) Earnings —
January 31, 2025 A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH Trial Milestone Phase 2
October 31, 2024 A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH Trial Milestone Phase 2
February 9, 2024 A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH Trial Milestone Phase 2
August 3, 2023 A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens Trial Milestone Phase 2
July 8, 2019 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia Trial Milestone Phase 2
March 2, 2019 Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.